The way fertility testing is carried out in the UK is beginning to change. Instead of attending multiple appointments and waiting weeks for results, couples can now complete testing at home and arrive at their first clinic visit with valuable information already available.
Sapyen, a diagnostics company trusted by IVF clinics including Avenues, has developed an at-home testing solution that combines male fertility hormone testing, female AMH testing, and laboratory semen analysis into one coordinated system.
The offering includes a male hormone panel measuring testosterone, FSH, and LH, alongside a female AMH test that provides an early indication of ovarian reserve. Each test is available at £69. These can be paired with a semen analysis, priced at £149, which is processed in a laboratory after at-home sample collection.
The innovation lies in how these tests are combined. Couples can now complete a meaningful fertility assessment before their first consultation, enabling clinicians to work with data from the outset rather than starting from scratch.
This shift has practical benefits. Traditional fertility pathways are often slowed by disconnected testing stages and delayed male participation. By involving both partners at the beginning, the process becomes more efficient, allowing quicker progression to clinical decisions.
The male testing element is especially noteworthy. While male factors contribute to approximately half of infertility cases, testing has historically centred on sperm analysis alone. By incorporating hormone testing, the approach provides a more comprehensive view of male reproductive health.
For women, AMH testing offers early insight that can help shape expectations and guide treatment planning. Sapyen’s logistics system supports at-home semen collection by ensuring samples reach laboratories without the usual time pressures, maintaining reliability in analysis.
For clinics, implementation is straightforward. Results are presented in familiar clinical formats and can be integrated without requiring additional systems. For patients, the process reduces complexity and shortens waiting times.
Overall, this model represents a shift in how fertility care begins — with both partners tested early, clinicians better informed, and a clearer path forward from the first consultation.
